Caliway Biopharmaceuticals (6919) Q4 2024 earnings summary

Executive summary

• Listed on the Taiwan Stock Exchange in October 2024, focusing on new drugs for aesthetic medicine and chronic inflammation.

• Revenue primarily from health food sales, with two major customers accounting for 100% of 2024 revenue.

• Significant capital raised through share issuance in 2024, strengthening cash position.

Financial highlights

• Operating revenue increased to $44,434 thousand in 2024 from $38,932 thousand in 2023, a 14% year-over-year growth.

• Net loss widened to $588,830 thousand in 2024 from $488,455 thousand in 2023.

• Gross margin improved to 31% in 2024 from 29% in 2023.

• Cash and cash equivalents rose to $6,901,490 thousand at year-end 2024, up from $3,422,152 thousand.

• Basic loss per share was NT$4.12 in 2024, compared to NT$3.94 in 2023.

Outlook and guidance

• Adoption of new IFRS standards expected to have minimal impact; ongoing evaluation of future standards.

• No guidance provided on future revenue or profitability.